Samsara Therapeutics
Matthew is providing Samsara with the most cutting-edge, physiologically and disease relevant neuronal cellular models. He develops assays in different neuronal cell populations derived from induced pluripotent stem cells (iPSCs) from patients diagnosed with neurodegenerative diseases, such as Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS).
Funded by the Motor Neurone Disease Association (MNDA), Matthew completed his DPhil at the University of Oxford, where he investigated the protective function of antioxidant proteins and their use as therapeutic targets in ALS. Following this, he undertook postdoctoral training in the Wade-Martins’ laboratory of molecular neurodegeneration. Working closely with industrial collaborators (Forma Therapeutics, Evotec, Celgene, Bristol Myers Squibb), his research investigated mitophagy dysfunction in PD. He also has a wealth of experience in high-content imaging, liquid handling and developing automated high-throughput cell-based assays.
Samsara Therapeutics
Samsara Therapeutics, Inc. is a biopharmaceutical company aiming to discover the first-in-class therapeutics that treat rare genetic and neurodegenerative diseases and extend a healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy.